ProfileGDS5678 / 1452624_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 30% 30% 30% 30% 30% 29% 30% 29% 30% 30% 30% 30% 30% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7314431
GSM967853U87-EV human glioblastoma xenograft - Control 22.6823430
GSM967854U87-EV human glioblastoma xenograft - Control 32.6849430
GSM967855U87-EV human glioblastoma xenograft - Control 42.6385230
GSM967856U87-EV human glioblastoma xenograft - Control 52.6291330
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7548130
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7061229
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6598330
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6319929
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6684830
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6679130
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6574230
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6752630
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6728430